Tıpta Yenilikçi Yaklaşımlar Dergisi
Abbreviation: JIAM | ISSN (Online): 2757-7589 | DOI: 10.29329/jiam

Derleme Makalesi    |    Açık Erişim
Tıpta Yenilikçi Yaklaşımlar Dergisi 2022, Cil. 3(2) 28-44

The Burden of Multi-drug Resistant Acinetobacter baumannii in Nigeria

Sani Mohammed, Adamu Almustapha Aliero, Dani̇el Dan-Inna Attah, Bashi̇r Abdulkadi̇r, Adamu Sale & Ahmad Ibrahi̇m Bagudo

ss. 28 - 44   |  DOI: https://doi.org/10.29329/jiam.2022.601.1

Yayın tarihi: Ekim 02, 2023  |   Okunma Sayısı: 71  |  İndirilme Sayısı: 99

PDF İndir

Özet

As a multidrug-resistant and invasive pathogen, Acinetobacter baumannii is one of the leading causes of nosocomial infections in the healthcare system. It has been recognized as a causative agent of pneumonia, sepsis, meningitis, urinary tract and wound infections. It is associated with high morbidity, mortality and healthcare costs due to treatment failure. Biomedical databases (Scopus, Medline, Web of Science, EBSCO, Google Scholar and PubMed) were searched and retrieved for all relevant manuscripts published in English. Eighty-six (86) documents were revived from previous researches of four different search engine, with a follow-up full-text evaluation of 35 publications for inclusion. Due to the lack of data on MDR A. baumannii in Africa, especially Nigeria, 10 articles were selected for this review. The results of ten selected articles showed that 4084 isolates of A. baumannii causing nosocomial infection were isolated from clinical specimens, of which 287 isolates of A. baumannii were detected. Antibiotics tested against identified A. boumannii belong to different classes which include: AMK: amikacin; CEF: ceftriaxone; GEN: gentamicin; IPM: imipenem; LVX: levofloxacin; MEM: meropenem; AMP: ampicillin; CIP: ciprofloxacin; AMX amoxicillin; SAL sulbactam and COL: colistin. The highest resistance was to GEN and the lowest to MEM. This review highlighted the burden of multidrug-resistant Acinetobacter baumannii to antibiotics in Nigeria. There is a need for continuous surveillance study on antimicrobial resistance in Nigeria, especially in primary healthcare which was abandoned by most researchers.

Anahtar Kelimeler: Multi-drug, Resistance, Acinetobacter baumannii, Nigeria

Bu makaleye nasıl atıf yapılır

APA 6th edition
Mohammed, S., Aliero, A.A., Attah, D.D., Abdulkadi̇r, B., Sale, A. & Bagudo, A.I. (2022). The Burden of Multi-drug Resistant Acinetobacter baumannii in Nigeria . Tıpta Yenilikçi Yaklaşımlar Dergisi, 3(2), 28-44. doi: 10.29329/jiam.2022.601.1

Harvard
Mohammed, S., Aliero, A., Attah, D., Abdulkadi̇r, B., Sale, A. and Bagudo, A. (2022). The Burden of Multi-drug Resistant Acinetobacter baumannii in Nigeria . Tıpta Yenilikçi Yaklaşımlar Dergisi, 3(2), pp. 28-44.

Chicago 16th edition
Mohammed, Sani, Adamu Almustapha Aliero, Dani̇el Dan-Inna Attah, Bashi̇r Abdulkadi̇r, Adamu Sale and Ahmad Ibrahi̇m Bagudo (2022). "The Burden of Multi-drug Resistant Acinetobacter baumannii in Nigeria ". Tıpta Yenilikçi Yaklaşımlar Dergisi 3 (2):28-44. doi:10.29329/jiam.2022.601.1.
Kaynakça
  1. Ali, I., Shabbir, M., & Iman, N. U. (2017). Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. JPMA, 67(1161). [Google Scholar]
  2. Al-Mously N, Hakawi A (2013). Acinetobacter baumannii bloodstream infections in a tertiary hospital: Antimicrobial resistance surveillance. Int J Infect Control. 9 (2):1-8. [Google Scholar]
  3. Asif Muhammad, Iqbal Ahmad Alvi, and Shafiq Ur Rehman (2018). Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities Infect Drug Resist. 11: 1249–1260. [Google Scholar]
  4. Bashir A., Garba I., Aliero A. A., Kibiya A., Abubakar M. H., Ntulume I., Faruk S., Ezera A. (2019). Superbugs-related prolonged admissions in three tertiary hospitals, Kano State, Nigeria. Pan African Medical Journal. 32(166). [Google Scholar]
  5. Bonomo R. A., Szabo D. (2006). Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis. 43 (Suppl 2):S49–56. [Google Scholar]
  6. Coelho JM, Turton JF, Kaufmann ME, Glover J, Woodford N, Warner M, Palepou MF, Pike R, Pitt TL, Patel BC, Livermore DM (2006). Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in Londonand Southeast England. J Clin Microbiol 44: 3623-3627. [Google Scholar]
  7. Dexter C., Murray G. L., Paulsen I. T., Peleg A. Y. (2015). Community-acquired Acinetobacter baumannii: clinical characteristics, epidemiology and pathogenesis. Expert Rev. Anti-Infect. Ther. 13, 567–573. [Google Scholar]
  8. Dijkshoorn L, Nemec A, Seifert H. (2007) An increasing threat in hospitals: multidrugresistant Acinetobacter baumannii. Nat Rev Microbiol 5: 939-51. [Google Scholar]
  9. Egwuenu A, Obasanya J, Okeke I, Aboderin O, Olayinka A, Kwange D, Ogunniyi A, Mbadiwe E, Omoniyei L, Omotayo H, Niyang M (2017). Antimicrobial use and resistance in Nigeria: situation analysis and recommendations, 2017. Pan African Medical Journal. 21. [Google Scholar]
  10. Elouennass M, Bajou T, Lemnouer AH, Foissaud V, Hervé V, Baaj AJ. (2003). Acinetobacter baumannii : étude de la sensibilité des souches isolées à l’hôpital militaire d’instruction MohammedV, Rabat, Maroc. Med Mal Infect. 33:361–364. [Google Scholar]
  11. Elouennass M,Sahnoun I, Zrara A, Bajjou T, Elhamzaoui S. (2008). Épidémiologie et profil de sensibilité des isolats d’hémoculture dans un unit de réanimation (2002–2005). Med Mal Infect. 38(1):18-24. [Google Scholar]
  12. Fasuyi OC, Ike WE, Ojo DA, Adeboye AO (2020). Plasmid profile of multidrug resistant Acinetobacter baumannii strains from wounds of patients attending Federal Medical Centre, Abeokuta, Southwest, Nigeria. Nigerian Journal of Pharmaceutical and Applied Science Research. 23;9(2):47-51. [Google Scholar]
  13. Giamarellou, H., Antoniadou, A. and Kanellakopoulou, K. (2008). Acinetobacter baumannii: A universal threat to public health. Int. J. Antimicrob. Agents. 32: 106-119. [Google Scholar]
  14. Hannah O Dada-Adegbola, BJ Brown, Arinola Sanusi, Jude Nwaokenye, Oluwasola O Obebe (2020). Antibiotic Susceptibility Pattern of Acinetobacter Species Isolated in Clinical Specimens from the University College Hospital, Ibadan, Nigeria African Journal of Health Sciences. 33 (5), 18-33 [Google Scholar]
  15. Ike WE, Adeniyi BA, Soge OO (2014). Prevalence of Multidrug Resistant Acinetobacter baumannii in Eight Tertiary Hospitals in Southwestern Nigeria. N Y Sci J . 7(11):86-93]. [Google Scholar]
  16. Ikechukwu Herbert Egwu, Ifeanyichukwu Romanus Iroha, Modesta Mmaduabuchi Egwu-Ikechukwu,  Ikemesit Udeme Peter,   Charity Chinyere Nnabugwu,   Chioma Margaret Ali,   Elom Emeka Elom,   Lillian Ngozika Ogene,   Christiana Inuaesiet Edemekong,   Ismaila Danjuma Mohammed (2021). Antimicrobial Susceptibility Pattern and Molecular Identification of Acinetobacter baumannii in Alex Ekwueme-Federal University Teaching Hospital Abakaliki, Nigeria Journal of Pharmaceutical Research International, Page 409-419 [Google Scholar]
  17. Iregbu KC, Ogunsola FT, Odugbemi TO. (2002). Infections caused by Acinetobacter species and their susceptibility to 14 antibiotics in Lagos University Teaching Hospital, Lagos. West Afr J Med. 21(3):226-9 [Google Scholar]
  18. Jaggi N, Sissodia P, Sharma L (2012). Acinetobacter baumannii isolates in a tertiary care hospital: Antimicrobial resistance and clinical significance. J Microbiol Infect Dis. 2(2): 57-63. [Google Scholar]
  19. Jyoti Tanwar, Shrayanee Das, Zeeshan Fatima, Saif Hameed (2014). Multidrug Resistance: An Emerging Crisis, Interdisciplinary Perspectives on Infectious Diseases, 7 pages. [Google Scholar]
  20. Kanafani, Z. A., Zahreddine, N., Tayyar, R., Sfeir, J., Araj, G. F., Matar, G. M., & Kanj, S. S. (2018). Multi-drug resistant Acinetobacter species: a seven-year experience from a tertiary care center in Lebanon. Antimicrobial Resistance & Infection Control, 7(1), 1-8. [Google Scholar]
  21. Khalifa Ben Haj A, Khedher M. (2010). Profil de sensibilité aux antibiotiques des souches d’ Acinetobacter baumannii isolées dans la région de Mahdia. Med Mal Infect.  40 :126–128. [Google Scholar]
  22. Lahsoune M, Boutayeb H, Zerouali K, Belabbes H, El Mdaghri N. (2007 ). Prévalence et état de sensibilité aux antibiotiques d’ Acinetobacter baumannii dans un CHU marocain. Med Mal Infect. 37 :828–831 [Google Scholar]
  23. Manchanda V, Sanchaita S, Singh N (2010). Multidrug resistant acinetobacter. J Glob Infect Dis. 2(3):291-304. [Google Scholar]
  24. Maragakis, L. L., and Perl, T. M. (2008). Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46:1254-1263. [Google Scholar]
  25. Marais E, de Jong G, Ferraz V, Maloba B, Dusé AG (2004). Inter-hospital transfer of pan-resistant Acinetobacter strains in Johannesburg, South Africa. Am J Infect Control 32: 278-281 [Google Scholar]
  26. Merkier AK, Catalano M, Ramirez MS, Quiroga C, Orman B, Ratier L, Famiglietti A, Vay C, Di Martino A, Kaufman S, Centron D (2008). Polyclonal spread of blaOXA-23 and blaOXA-58 in Acinetobacter baumannii isolates from Argentina. J Infect Developing Countries. 2:235-240. [Google Scholar]
  27. Nemec A., Radolfova-Krizova L., Maixnerova M., Vrestiakova E., Jezek P., Sedo O. (2016). Taxonomy of haemolytic and/or proteolytic strains of the genus Acinetobacter with the proposals of Acinetobacter courvalinii sp. nov. (genomic species 14 sensu Bouvet & Jeanjean), Acinetobacter dispersus sp. nov. (genomic species 17), Acinetobacter modestus sp. nov., Acinetobacter proteolyticus sp. nov. and Acinetobacter vivianii sp. nov. International Journal of Systematic and Evolutionary Microbiology 66(4):1673-1685 [Google Scholar]
  28. Ntusi NB, Badri M, Khalfey H, Whitelaw A, Oliver S, Piercy J, Raine R, Joubert I, Dheda K. (2012). ICU-Associated Acinetobacter baumannii Colonisation/Infection in a High HIV Prevalence Resource-Poor Setting. PLoS One. 7(12): e52452. [Google Scholar]
  29. Odewale, G., O. J. Adefioye, J. Ojo, F. A. Adewumi, O. A. Olowe (2016). Multidrug Resistance of Acinetobacter baumannii in Ladoke Akintola University Teaching Hospital, Osogbo, Nigeria Eur J Microbiol Immunol (Bp).  6(3): 238–243. [Google Scholar]
  30. Peleg AY, Seifert H, Paterson DL. (2008). Acinetobacter baumannii: emergence of a successful pathogen. Clinical microbiology reviews. 21(3):538-82. [Google Scholar]
  31. Poirel L, Mansour W, Bouallegue O, Nordmann P (2008) Carbapenem-resistant Acinetobacter baumannii isolates from Tunisiaproducing the OXA-58-like carbapenem-hydrolyzingoxacillinase OXA-97.Antimicrob Agents Chemother 52: 1613-1617. [Google Scholar]
  32. Punpanich W, Nithitamsakun N, Treeratweeraphong V, Suntarattiwong P.(2012). Risk factors for carbapenem non-susceptibility and mortality in Acinetobacter baumannii bacteremia in children. Int J Infect Dis. 16(11):e811-e815. [Google Scholar]
  33. Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J, Davies TA. (2012). Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: results from Capital Surveillance.  Diagn Microbiol Infect Dis. 73(3):267-70. [Google Scholar]
  34. Schulte B, Goerke C,Weyrich P, Gröbner S, Bahrs C, Wolz C, Autenrieth IB, Borgmann S. (2005). Clonal spread of meropenem-resistant Acinetobacter baumannii strains in hospitals in the Mediterranean region and transmission to south-west Germany. J Hosp Infect 61: 356-7. [Google Scholar]
  35. Shu’aibu, S. S., A. Arzai, M. Mukhtar (2021). Antibiotic Susceptibility Profile and Prevalence of AmpC among Clinical Bacterial Isolates obtained From Northwestern Nigeria UMYU journal of microbiology 5(8), 2015 [Google Scholar]
  36. Silvia L., Munoz-Price & Weinstein, R. A (2008). The authors reply. New England Journal of Medicine, 358(26), 2846-2847. [Google Scholar]
  37. Simor AE, Lee M, Vearncombe M, Jones-Paul L, Barry C, Gomez M, Fish JS, Cartotto RC, Palmer R, Louie M. (2002). An outbreak due to multirésistant Acinetobacter baumannii in burn unit: Risk factors for acquisition and management. Infect Control Hosp Epidemiol. 23(5), 261-267. [Google Scholar]
  38. Victor Ugochukwu Nwadike, Chiedozie Kingsley Ojide, Eziyi Iche Kalu (2014). Multidrug resistant acinetobacter infection and their antimicrobial susceptibility pattern in a Nigerian tertiary hospital ICU. Afr J Infect Dis. 8(1):14-8 [Google Scholar]
  39. Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, Woodford N, Livermore D, QuinnJP, and the Colombian Nosocomial Bacterial Resistance Study Group (2007) Dissemination of Acinetobacter baumannii clones with OXA-23 carbapenemase in Colombian hospitals. Antimicrob Agents Chemother 51: 2001-2004. [Google Scholar]
  40. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. (2019). EPIC II Group of Investigators. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA. 302(21):2323-2329. [Google Scholar]
  41. Wang S. H., Sheng W. H., Chang Y. Y., Wang L. H., Lin H. C., Chen M. L., Pan H. J., Ko W. J., Chang S. C., Lin F. Y. (2003). Healthcare-associated outbreak due to pan-drug resistant Acinetobacter baumanii in a surgical intensive care unit, J Hosp Infect 53, 97–102 [Google Scholar]
  42. Xiao YH, Giske CG, Wei ZQ, Shen P, Heddini A, Li LJ. (2011). Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist Updat. 14(4-5): 236-250. [Google Scholar]
  43. Zarrilli Raffaele, Maria Giannouli, Federica Tomasone, Maria Triassi, Athanassios Tsakris (2009). Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities J Infect DevCtries .3(5):335-341. [Google Scholar]
Meta
Cil. 3 (2)
İndir
Metric
Geçmiş
Benzer

Cilt 3 Sayı 2

Aralık 2022

Tüm Makaleler
Copyright © 2012 - 2024 Tıpta Yenilikçi Yaklaşımlar Dergisi.
Pen Academic Publishing is a trademark of THDSoft.
This work is licensed under a Creative Commons Attribution 4.0 International License. CC BY-NC-ND
Electronic Journal Management System. This software was developed in Türkiye. ejournal.gen.tr
Pen Academic Publishing General Publication Policy: